Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Trading 09-25 11:24:29 EDT

2.31

-0.02

-1.07%

High2.37	Low2.27	Vol412.82K
Open2.34	D1 Closing2.33	Amplitude4.08%
Mkt Cap276.60M	Tradable Cap241.88M	Total Shares120.00M
T/O953.55K	T/O Rate0.39%	Tradable Shares104.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":2.305,"timestamp":1790349836094,"preClose":2.33,"halted":0,"volume":412822,"delay":0,"changeRate":-0.010729613733905541,"floatShares":104935918,"shares":120000000,"eps":-1.052849,"marketStatus":"Trading","change":-0.025,"latestTime":"09-25 11:24:29 EDT","open":2.34,"high":2.365,"low":2.27,"amount":953545.6679416001,"amplitude":0.040773,"askPrice":2.31,"askSize":1640,"bidPrice":2.3,"bidSize":1771,"shortable":3,"etf":0,"ttmEps":-1.052849,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790366400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":2.33,"preHourTrading":{"tag":"盘前","latestPrice":2.38,"preClose":2.33,"latestTime":"09:22 EDT","volume":2434,"amount":5817.589807,"timestamp":1790342565611,"change":0.05,"changeRate":0.021459,"amplitude":0.030043},"postHourTrading":{"tag":"盘后","latestPrice":2.36,"preClose":2.33,"latestTime":"19:49 EDT","volume":5868,"amount":13679.1472,"timestamp":1790293758600,"change":0.03,"changeRate":0.012876,"amplitude":0.012876},"volumeRatio":0.760384,"impliedVol":0.3313,"impliedVolPercentile":0.0598},"requestUrl":"/m/hq/s/FATE","defaultTab":"news","newsList":[{"id":"2670440027","title":"Sector Update: Healthcare Stocks Edge Higher Premarket Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2670440027","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670440027?lang=en_us&edition=fundamental","pubTime":"2026-09-25 21:19","pubTimestamp":1790342373,"startTime":"0","endTime":"0","summary":"Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) advancing by 0.5%.STAAR Surgical (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2168564149.EUR","WDNA","LU0061475181.USD","LU2750360641.GBP","LU2089284900.SGD","SGXZ81514606.USD","LU1145028129.USD","LU0354030438.USD","LU0266013472.USD","LU1720051108.HKD","SGXZ57979304.SGD","IE00BJJMRZ35.SGD","SG9999014906.USD","LU2896262040.SGD","TRUH","IE00B1XK9C88.USD","LU1989771016.USD","LU0320765059.SGD","LU2023251221.USD","LU0234572021.USD","LU2324357040.USD","LU0708995401.HKD","LU2417539215.USD","LU0174119429.USD","LU0323591593.USD","LU2471134879.HKD","LU0466842654.USD","LU0672654240.SGD","LU1291159041.SGD","LLYZ","SGXZ31699556.SGD","RXL","LU1035775433.USD","GB00BDT5M118.USD","LU2264538146.SGD","LU2063271972.USD","NKTR","LU0471298777.SGD","IE00BN29S564.USD","LU0882574055.USD","LU2028103732.USD","IE00BKPKM429.USD","LU0256863811.USD","LU0471298694.HKD","SG9999015978.USD","LU1548497426.USD","SGXZ51526630.SGD","IE00BKDWB100.SGD","LU0823434740.USD","LU0943347566.SGD","SG9999017495.SGD","LU2552382132.HKD","LU0133085943.USD","LU2471134796.USD","LU2756315664.SGD","LU0320765992.SGD","LU0058720904.USD","LU1093756325.SGD","LU1983299246.USD","TMED","SG9999013999.USD","LU1323610961.USD","IBB","LU0689472784.USD","BK4516","LU1280957306.USD","LLII","LU1623119135.USD","LU1979441026.SGD","XBI","LU0094547139.USD","LU2111349929.HKD","SG9999015952.SGD","LU0316494557.USD","LU1988902786.USD","LU2468319806.SGD","IE00BK4W5L77.USD","LU0640476718.USD","LU2237438978.USD","LU2237443549.SGD","FHLC","LU2552382058.USD","LU2265009873.SGD","LU0417517546.SGD","LU2491050071.SGD","LU0432979614.USD","LU2168564065.EUR","LU1868836591.USD","LU2168564495.EUR","LU1814569148.SGD","LU2168563687.JPY","LU2237443382.USD","LU2271345857.HKD","LU0006306889.USD","BK4139","SG9999018865.SGD","LU1868837300.USD","CURE","LU0345770993.USD","LU0385154629.USD","LU2237443978.SGD","LU2360106947.USD","THNR","IE00B2B36J28.USD","LU1551013425.SGD","ILDR","SG9999015945.SGD","BK4198","LU2168564222.USD","LU1720051017.SGD","ELIL","IE0009355771.USD","LU0683600562.USD","IE00B4JS1V06.HKD","LU0456855351.SGD","IE00BFSS7M15.SGD","LU0787776722.HKD","LU2602419157.SGD","LU0820562030.AUD","BK4599","FTXH","LU1917777945.USD","SG9999014880.SGD","LU0238689110.USD","ELIS","IE00B7KXQ091.USD","LU0964807845.USD","LU1064131342.USD","LU2106854487.HKD","LU0122379950.USD","IE00B775H168.HKD","LU0158827948.USD","IE00BJJMRX11.SGD","SGXZ99366536.SGD","LU0353189680.USD","IE0001KFT4U8.USD","LLY","PJP","LU0079474960.USD","LU1868836757.USD","LU2746668974.SGD","LU0820561909.HKD","IE00BFSS8Q28.SGD","IE00BK4W5M84.HKD","CANC","LU0097036916.USD","LU2023250504.SGD","SG9999014914.USD","LU0823416689.USD","BK4588","LU0109391861.USD","LU0345770308.USD","LU2462157665.USD","LU2087625088.SGD","LU2357305700.SGD","IHE","IXJ","BK4534","IYH","LU0106261372.USD","LU0289739699.SGD","BK4533","LU2237443465.HKD","PPH","IE0004445239.USD","BK4581","LU2750360997.AUD","LU1974910355.USD","LU0109394709.USD","LABU","SG9999001176.SGD","IE00BJJMRY28.SGD","SG9999018857.SGD","LU2746668461.USD","LU0096364046.USD","IE00BJLML261.HKD","LU2089984988.USD","OZEM","IE0005OL40V9.USD","LU2023250330.USD","IE00B1BXHZ80.USD","LU0820561818.USD","VHT","LLYX","LU0210536198.USD","LU2237443895.HKD","LU1093756168.USD","HRTS","MHIP","IE00BJT1NW94.SGD","IE0004445015.USD","JDOC","LU0225283273.USD","LU1868836914.USD","LU1868837136.USD","LU0882574139.USD","LU2213496289.HKD","LU2456880835.USD","LU2462591350.SGD","IE00B4R5TH58.HKD","LU2361044865.SGD","LU0203201768.USD","LU0256863902.USD","LU1057294990.SGD","LU1712237335.SGD","LU2236285917.USD","AGNG","LU0786609619.USD","LU2461242641.AUD","LU1804176565.USD","LU0158827781.USD","LU1127390331.HKD","LU2471134523.USD","LU2552382215.SGD","LU2756315318.SGD","IE0002141913.USD","GDOC","BK4007","LU0823434583.USD","LU2361045086.USD","LU1061106388.HKD","LU1629891620.HKD","LU0354030511.USD","LU2089283258.USD","LU1366192091.USD","LU2108987350.USD","SG9999001176.USD","STAA","LU1551013342.USD","LU2491050154.USD","BK4585","XLV","LU1232071149.USD","LU0198837287.USD","LU2211815571.USD","LU2112291526.USD","LU0203202063.USD","IE00BFTCPJ56.SGD","LU0353189763.USD","SG9999015986.USD","BK4548","SG9999014898.SGD","LU2361044949.HKD","MEDI","FATE","LU1691799644.USD","LU2491049909.HKD","LU1069344957.HKD","MEDX","LU1267930730.SGD","IE00BWXC8680.SGD","LU0889565916.HKD","LU2237443622.USD","LU1023059063.AUD","LU2471134952.CNY","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670144287","title":"Fate Therapeutics - Receives $15 Mln Award for Phase 2 FT819 Trial in Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2670144287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670144287?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:01","pubTimestamp":1790334093,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nFWN45G1D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670381442","title":"Fate Therapeutics Wins $15 Million CIRM Grant for FT819 Lupus Nephritis Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2670381442","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670381442?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:01","pubTimestamp":1790334067,"startTime":"0","endTime":"0","summary":"Fate Therapeutics wins $15 million CIRM grant for FT819 lupus nephritis Phase 2 trialFate Therapeutics won a USD 15 million CLIN2 grant from the California Institute for Regenerative Medicine to advan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nNDL5QD4M0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014013.SGD","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","SG9999014039.USD","IE00BQXX3F31.USD","LU2210149790.SGD","LU2095319765.USD","LU0314104364.USD","IE00BN0W2T93.GBP","BK4112","LU2210150020.SGD","FATE","IE00BN0W2V16.EUR","BCDF","BK4139","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","BK4585","IE00BQXX3D17.EUR","IE00BKPKM429.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607273","title":"Fate Therapeutics Launches Phase 1/2 Complete Trial of FT839 Dual-CAR T Therapy in Rheumatoid Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607273","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607273?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:01","pubTimestamp":1789556500,"startTime":"0","endTime":"0","summary":"Fate Therapeutics launches Phase 1/2 COMPLETE trial of FT839 dual-CAR T therapy in rheumatoid arthritisFate Therapeutics secured four ACR Convergence 2026 poster slots for its off-the-shelf CAR T-cell","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDLbxzZcj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","NDAQ","SG9999014005.SGD","LU2210150020.SGD","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","LU2095319765.USD","FATE","IE00B3QW5Z07.USD","SG9999014039.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BCDF","IE00BN0W2T93.GBP","BK4588","BK4112","SG9999014013.SGD","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538541","title":"Fate Therapeutics announces clinical data from FT819 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538541?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:45","pubTimestamp":1788954325,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (FATE) announced clinical data from its off-the-shelf anti-CD19 CAR T-cell product candidate FT819, and pre-clinical data from it...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-announces-clinical-data-from-ft819-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-announces-clinical-data-from-ft819-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4022","FATE","BK4230","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666631587","title":"Fate Therapeutics Presents Phase 1 Data for Off-the-Shelf CAR-T FT819 in Systemic Lupus Erythematosus at CCR-West 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2666631587","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666631587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:06","pubTimestamp":1788951970,"startTime":"0","endTime":"0","summary":"Fate Therapeutics presents Phase 1 data for off-the-shelf CAR-T FT819 in systemic lupus erythematosus at CCR-West 2026Fate Therapeutics set an encore clinical data presentation on FT819 at the CCR – W","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL9RfVnK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","BK4139","IE00BN0W2V16.EUR","BK4588","NDAQ","IE00BQXX3F31.USD","BK4585","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4112","FATE","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BCDF","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU0314104364.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666858794","title":"Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666858794","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666858794?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358477/24675/en/fate-therapeutics-announces-encore-clinical-data-presentation-of-ft819-off-the-shelf-car-t-cell-product-candidate-at-the-ccr-west-2026-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","BK4077","SLE","IDNA","BMED","GDOC","NVIB","BK4139","HYLG","FATE","CCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664876078","title":"Fate Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat on FT819 Autoimmune CAR-T Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2664876078","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664876078?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:03","pubTimestamp":1788433419,"startTime":"0","endTime":"0","summary":"Fate Therapeutics joins Cantor Global Healthcare Conference fireside chat on FT819 autoimmune CAR-T programFate Therapeutics management will join a fireside chat at the 2026 Annual Cantor Global Healt","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL7WdDvt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BN0W2V16.EUR","BCDF","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","FATE","BK4585","BK4139","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4588","SG9999014039.USD","LU2210150020.SGD","NDAQ","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014021.USD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664584356","title":"Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664584356","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664584356?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:31","pubTimestamp":1788366686,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc ($FATE) announced an update on their ongoing clinical study. Fate Therapeutics Inc. is advancing a new early stage trial call...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-expands-into-autoimmune-disease-with-new-ft839-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-expands-into-autoimmune-disease-with-new-ft839-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659177808","title":"Fate Therapeutics intiates first patient in RECLAIM-LN trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659177808","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659177808?lang=en_us&edition=fundamental","pubTime":"2026-08-16 21:40","pubTimestamp":1786887614,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (FATE) highlighted the initiation of and treatment of the first patient in RECLAIM-LN, its Phase 2 potentially registrational cli...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-intiates-first-patient-in-reclaim-ln-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-intiates-first-patient-in-reclaim-ln-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144490","title":"Fate Therapeutics Price Target Maintained with a $7.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144490","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144490?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:20","pubTimestamp":1786713600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FATE/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659314328","title":"Fate Therapeutics - Patients to Receive Single 900 Mln-Cell Dose of Ft819; Primary Endpoint at Week 26","url":"https://stock-news.laohu8.com/highlight/detail?id=2659314328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659314328?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA8L2JHJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659143408","title":"Fate Therapeutics Initiates Potentially Registrational Reclaim-Ln Clinical Trial of FT819 for the Treatment of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2659143408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659143408?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA8L2JHJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659450421","title":"Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2659450421","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659450421?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345223/24675/en/fate-therapeutics-initiates-potentially-registrational-reclaim-ln-clinical-trial-of-ft819-for-the-treatment-of-lupus-nephritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR","BK4230","IDNA","BK4022","MEDX","FATE","HYLG","NVIB","BK4077","LABU","SLE","BMED","BK4139","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659673481","title":"Equillium Q2 Post Narrower Net Loss than Expected; Starts R&D Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2659673481","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659673481?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:20","pubTimestamp":1786652418,"startTime":"0","endTime":"0","summary":"Equillium Q2 post narrower net loss than expected; starts R&D initiativesOverviewUS biotech innovator's Q2 net loss narrowed and beat analyst expectationsQ2 loss per share beat analyst expectationsCom","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A159:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQ","BK4007","ARTL","NKTX","BK4139","BK4505","BK4568","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659169563","title":"Analysts Conflicted on These Healthcare Names: Fate Therapeutics (FATE) and Mediwound (MDWD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659169563","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659169563?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:50","pubTimestamp":1786639807,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE) and Mediwound (MDWD). Fat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-fate-therapeutics-fate-and-mediwound-mdwd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-fate-therapeutics-fate-and-mediwound-mdwd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","XLV","BK4139","MDWD","FATE","BK4137","BK4581","BK4585","BK4588","HCSG","LABU","LU0128526141.USD","XBI","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659163408","title":"Fate Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659163408","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659163408?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:54","pubTimestamp":1786632885,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryFate Therapeutics IncFATE.OQreported a quarterly adjusted loss of 25 cents per share for the quarter ended June 30","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A1NQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659527901","title":"Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659527901","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659527901?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:55","pubTimestamp":1786625739,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.79 percent increase over losses of $(0.29) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61173030/fate-therapeutics-q2-eps-0-25-beats-0-27-estimate-sales-2-082m-beat-1-366m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659523471","title":"Fate Therapeutics - Expects Operating Runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2659523471","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659523471?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA3Y20RN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659547741","title":"Fate Therapeutics Q2 Operating Expenses USD 33.216 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659547741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659547741?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX4MD16F:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0754},{"period":"1month","weight":-0.0863},{"period":"3month","weight":0.1095},{"period":"6month","weight":0.9915},{"period":"1year","weight":1.3069},{"period":"ytd","weight":1.3713}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.2099},{"period":"1year","weight":0.1605},{"period":"ytd","weight":0.125}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.049458},{"month":2,"riseRate":0.615385,"avgChangeRate":0.078089},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.020579},{"month":4,"riseRate":0.615385,"avgChangeRate":0.004138},{"month":5,"riseRate":0.461538,"avgChangeRate":0.079338},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.000833},{"month":7,"riseRate":0.384615,"avgChangeRate":0.039214},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.024594},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.001267},{"month":10,"riseRate":0.25,"avgChangeRate":-0.091603},{"month":11,"riseRate":0.538462,"avgChangeRate":0.090829},{"month":12,"riseRate":0.538462,"avgChangeRate":0.045045}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction